Cardiol Therapeutics (CRDL) Assets Average (2021 - 2026)

Cardiol Therapeutics' Assets Average history runs 6 years deep, the most recent figure standing at $19.9 million for Q1 2026.

• Quarterly Assets Average fell 1.75% year-over-year to $19.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.9 million (down 1.75% YoY) and the FY2025 annual result came in at $19.9 million, down 20.13% from the prior year.
• Assets Average was $19.9 million for Q1 2026 at Cardiol Therapeutics, up from $13.2 million in the prior quarter.
• Across five years, Assets Average topped out at $66.2 million in Q1 2022 and bottomed at $11.9 million in Q3 2025.
• A 5-year average of $31.5 million and a median of $25.0 million in 2024 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2022 — Assets Average surged 100.82% — and 2024, when it tumbled 52.28%.
• Cardiol Therapeutics' Assets Average stood at $49.1 million in 2022, then slumped by 39.79% to $29.5 million in 2023, then slumped by 39.65% to $17.8 million in 2024, then decreased by 26.1% to $13.2 million in 2025, then surged by 51.22% to $19.9 million in 2026.
• Business Quant data shows CRDL's Assets Average at $19.9 million in Q1 2026, $13.2 million in Q4 2025, and $11.9 million in Q3 2025.